First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
Related Articles
FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS
The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.
ESMO Course in Medical Oncology for Medical Students Valencia
This interactive educational course aims to attract and motivate medical students to commit to working in this fast-evolving field
Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer
Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.
Tislelizumab Plus Chemotherapy Is Active, Tolerable in Advanced Gastric/GEJ Cancer
Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.
HR-1701 Plus Chemo Reduces Myelosuppression in HER2-Negative Gastric and GEJ Adenocarcinoma
SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.
Evorpacept Plus TRP Generates Superior Antitumor Responses, Survival Outcomes in HER2+ Gastric/GEJ Cancer
Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.
Dr Lang on Real-World Outcomes With the KEYNOTE-522 Regimen in Early-Stage TNBC
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Clinical Case Evolution: Disease Progression Patterns After Initial Therapy
Panelists discuss how myelofibrosis can evolve following initial treatment, examining common patterns of disease progression and strategies for adapting therapeutic approaches based on individual patient…
Simplifying clinical use of TCGA molecular subtypes through machine learning models
In this issue of Cancer Cell, Ellrott et al. present machine learning models to classify samples into The Cancer Genome Atlas (TCGA) molecular subtypes using compact…
View From the Other Side of the Stethoscope: On Love &… : Oncology Times
An abstract is unavailable.
